Your browser doesn't support javascript.
loading
Results of accelerated partial breast irradiation in patients not suitable for external beam irradiation stratified by GEC-ESTRO, ASTRO, and ABS guidelines.
Campos Magalhães Garcia, Luísa Sofia; Garcia Trigo, Maria Lurdes.
Afiliação
  • Campos Magalhães Garcia LS; Department of Radiotherapy, Centro Hospitalar Universitário de São João, Porto, Portugal. Electronic address: sofia_garcia_1990@hotmail.com.
  • Garcia Trigo ML; Department of Brachytherapy, Instituto Português de Oncologia do Porto Francisco Gentil E.P.E., Porto, Portugal.
Brachytherapy ; 20(2): 315-325, 2021.
Article em En | MEDLINE | ID: mdl-33199176
ABSTRACT

PURPOSE:

This study aims to review the outcome of an institution in multicatheter/interstitial accelerated partial breast irradiation (MC-APBI) for treatment of patients with breast cancer, either with strong criteria for APBI or unable to be treated with whole-breast irradiation. The outcomes were also stratified by the American Society for Radiation Oncology, American Brachytherapy Society, and Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology patient selection criteria.

METHODS:

The study includes 118 patients and 120 MC-APBI treatments, treated in a single tertiary center, between November 2003 and August 2016. The analysis is focused on the clinical baseline characteristics, local control, relapse-free survival, disease-specific survival (DSS), and overall survival.

RESULTS:

In accordance to the American Society for Radiation Oncology, American Brachytherapy Society, and Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology, 17.1% were "unsuitable," 19.2% were "unacceptable," and 19.5% were "high risk," respectively. The main reasons why high-risk patients were submitted to MC-APBI were as follows cardiopathy (n = 7), social difficulties (n = 4), and mobility limitations (n = 4). At the median followup period of 86.5 months, ipsilateral breast tumor recurrence was observed in one (0.8%) patient. The 3-year and 5-year relapse-free survival were 100% and 99.1%, respectively. DSS was 100%.

CONCLUSIONS:

This study demonstrated excellent control rates, DFS, and DSS of MC-APBI, rendering APBI as an excellent treatment for patients with breast cancer, even those who are not necessarily eligible for this treatment approach. The selection criteria for ABPI diverge according to different guidelines and are based on studies with discrepancies, making extremely possible that these recommendations could be changed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias da Mama Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias da Mama Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article